{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:58:41Z","timestamp":1792112321267,"version":"4.4.0"},"reference-count":67,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T00:00:00Z","timestamp":1697328000000},"content-version":"unspecified","delay-in-days":14,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Ment Health"],"accepted":{"date-parts":[[2023,9,2]]},"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:sec>\n                    <jats:title>Question<\/jats:title>\n                    <jats:p>This umbrella review and guidelines aimed to provide evidence to support the rational choice of selected adjunctive therapies for schizophrenia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study selection and analysis<\/jats:title>\n                    <jats:p>Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and World Federation of Societies of Biological Psychiatry (WFSBP)-grading recommendations, 63 randomised control trials (RCTs) (of which 4219 unique participants have completed the RCTs) and 29 meta-analyses were analysed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings<\/jats:title>\n                    <jats:p>Provisional recommendations (WFSBP-grade 1) could be made for two molecules in augmentation to antipsychotics: (1) N-acetyl-cysteine (NAC, 1200\u20133600\u2009mg\/day, for &gt;12 consecutive weeks) in improving negative symptoms, general psychopathology (positive and negative syndrome scale for schizophrenia (PANSS) general psychopathology factor (G)-G subscale), with the RCTs with the longer duration showing the most robust findings; (2) polyunsaturated fatty acids (3000\u2009mg\/day of eicosapentaenoic acid, for &gt;12 weeks) in improving general psychopathology. Weaker recommendations (ie, WFSBP-grade 2) could be drawn for sarcosine (2\u2009g\/day) and minocycline (200\u2013300\u2009mg\/day) for improving negative symptoms in chronic schizophrenia (not early schizophrenia), and NAC for improving positive symptoms and cognition. Weak recommendations are not ready for clinical practice. There is provisional evidence that oestrogens and raloxifene are effective in some patients, but further research is needed to determine their benefit\/risk ratio.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The results of this umbrella review should be interpreted with caution as the number of RCTs included in the meta-analyses was generally small and the effect sizes were weak or medium. For NAC, two RCTs with low risk of bias have provided conflicting results and the WFSBP-grade recommendation included also the results of meta-analyses. These drugs could be provisionally prescribed for patients for whom no other treatments have been effective, but they should be discontinued if they prove ineffective.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjment-2023-300771","type":"journal-article","created":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T04:25:23Z","timestamp":1697603123000},"page":"e300771","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":30,"title":["Adjunctive agents to antipsychotics in schizophrenia: a systematic umbrella review and recommendations for amino acids, hormonal therapies and anti-inflammatory drugs"],"prefix":"10.1136","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3249-2030","authenticated-orcid":false,"given":"Guillaume","family":"Fond","sequence":"first","affiliation":[{"name":"Department of psychiatry, Assistance Publique des H\u00f4pitaux de Marseille, Marseille, France"},{"name":"Fondation FondaMental, Creteil, France"},{"name":"CEReSS-Health Service Research and Quality of Life Center, AMU, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmina","family":"Mallet","sequence":"additional","affiliation":[{"name":"Fondation FondaMental, Creteil, France"},{"name":"Department of Psychiatry, Louis Mourier Hospital, Colombes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Urbach","sequence":"additional","affiliation":[{"name":"Fondation FondaMental, Creteil, France"},{"name":"Department of Adult Psychiatry and Addictology, Centre Hospitalier de Versailles, Le Chesnay, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael Eriksen","family":"Benros","sequence":"additional","affiliation":[{"name":"Copenhagen Research Center for Biological and Precision Psychiatry, Mental Health Centre Copenhagen, Copenhagen, Denmark"},{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Berk","sequence":"additional","affiliation":[{"name":"Deakin University, School of Medicine, and Barwon Health; IMPACT, the Institute for Mental and Physical Health and Clinical Translation; Orygen The National Centre of Excellence in Youth Mental Health, The Florey Institute of Neuroscience and Mental Health and the Department of Psychiatry, University of Melbourne and the Department of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Billeci","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Reproductive Sciences, and Dentistry, Section of Psychiatry, Federico II University of Naples, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1229-6622","authenticated-orcid":false,"given":"Laurent","family":"Boyer","sequence":"additional","affiliation":[{"name":"CEReSS-Health Service Research and Quality of Life Center, AMU, Marseille, France"},{"name":"D\u00e9partement d'information m\u00e9dicale, Assistance Publique des H\u00f4pitaux de Marseille, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph U","family":"Correll","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Zucker Hillside Hospital, Glen Oaks, New York, USA"},{"name":"Department of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra\/Northwell, Hempstead, NY, USA"},{"name":"Department of Child and Adolescent Psychiatry, Charit\u00e9 Universit\u00e4tsmedizin Berlin, Berlin, Germany"},{"name":"German Center for Mental Health (DZPG), partner site Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9647-0853","authenticated-orcid":false,"given":"Michele","family":"Fornaro","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Reproductive Sciences, and Dentistry, Section of Psychiatry, Federico II University of Naples, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayashri","family":"Kulkarni","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Monash Alfred Psychiatry Research Centre, Alfred Hospital and Monash University Central Clinical School, Monash University,607StKildaRd, Level4, Melbourne, Victoria, Australia 3004, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Leboyer","sequence":"additional","affiliation":[{"name":"Fondation FondaMental, Creteil, France"},{"name":"Department of psychiatry, Univ Paris-Est-Cr\u00e9teil (UPEC), AP-HP, H\u00f4pitaux Universitaires \u00ab H. Mondor \u00bb, DMU IMPACT, INSERM U955, IMRB, translational Neuropsychiatry, F-94010 Creteil, France, Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Michel","family":"Llorca","sequence":"additional","affiliation":[{"name":"Fondation FondaMental, Creteil, France"},{"name":"D\u00e9partement de psychiatrie, Universit\u00e9 Clermont Auvergne, CMP-B CHU, CNRS,Clermont Auvergne INP, Institut Pascal, Clermont-Ferrand, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Misdrahi","sequence":"additional","affiliation":[{"name":"Fondation FondaMental, Creteil, France"},{"name":"Departement de Psychiatrie G\u00e9n\u00e9rale et Universitaire, Centre Hospitalier Charles Perrens; Univ. Bordeaux, CNRS, UMR 5287, F-33000, INCIA, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Rey","sequence":"additional","affiliation":[{"name":"Fondation FondaMental, Creteil, France"},{"name":"Schizophrenia Expert Centre, Le Vinatier Hospital; INSERM, U1028; CNRS, UMR5292; University Lyon 1; Lyon Neuroscience Research Center, PSYR2 Team, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Sch\u00fcrhoff","sequence":"additional","affiliation":[{"name":"Fondation FondaMental, Creteil, France"},{"name":"Department of psychiatry, Univ Paris-Est-Cr\u00e9teil (UPEC), AP-HP, H\u00f4pitaux Universitaires \u00ab H. Mondor \u00bb, DMU IMPACT, INSERM U955, IMRB, translational Neuropsychiatry, F-94010 Creteil, France, Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4877-7233","authenticated-orcid":false,"given":"Marco","family":"Solmi","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Ottawa, Ottawa, Ontario, Canada"},{"name":"Department of Mental Health, The Champlain First Episode Psychosis Program, The Ottawa Hospital, Ottawa, Ontario, Canada"},{"name":"Ottawa Hospital Research Institute (OHRI) Clinical Epidemiology Program University of Ottawa, Ottawa Hospital Research Institute (OHRI), Ottawa, Ontario, Canada"},{"name":"Department of Child and Adolescent Psychiatry, Charit\u00e9 Universit\u00e4tsmedizin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris E C","family":"Sommer","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University Medical Center Groningen (UMCG), Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M","family":"Stahl","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of California, San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0526-3136","authenticated-orcid":false,"given":"Baptiste","family":"Pignon","sequence":"additional","affiliation":[{"name":"Fondation FondaMental, Creteil, France"},{"name":"Department of psychiatry, Univ Paris-Est-Cr\u00e9teil (UPEC), AP-HP, H\u00f4pitaux Universitaires \u00ab H. Mondor \u00bb, DMU IMPACT, INSERM U955, IMRB, translational Neuropsychiatry, F-94010 Creteil, France, Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Berna","sequence":"additional","affiliation":[{"name":"Fondation FondaMental, Creteil, France"},{"name":"Psychiatry, Strasbourg University Hospital, University of Strasbourg, Strasbourg, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,10,18]]},"reference":[{"key":"2025082702230026000_26.1.e300771.1","doi-asserted-by":"crossref","first-page":"345","DOI":"10.31887\/DCNS.2010.12.3\/jkane","article-title":"Pharmacologic treatment of schizophrenia","volume":"12","author":"Kane","year":"2010","journal-title":"Dialogues Clin Neurosci"},{"key":"2025082702230026000_26.1.e300771.2","doi-asserted-by":"crossref","first-page":"15067","DOI":"10.1038\/nrdp.2015.67","article-title":"Schizophrenia","volume":"1","author":"Kahn","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"2025082702230026000_26.1.e300771.3","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.tins.2018.12.004","article-title":"Schizophrenia, dopamine and the striatum: from biology to symptoms","volume":"42","author":"McCutcheon","year":"2019","journal-title":"Trends Neurosci"},{"key":"2025082702230026000_26.1.e300771.4","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2012.57"},{"key":"2025082702230026000_26.1.e300771.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2020.09.028"},{"key":"2025082702230026000_26.1.e300771.6","doi-asserted-by":"publisher","DOI":"10.1177\/0706743717718167"},{"key":"2025082702230026000_26.1.e300771.7","doi-asserted-by":"crossref","DOI":"10.1159\/000493367","article-title":"Could some patients with treatment-resistant schizophrenia have reversible conditions","volume":"87","author":"Mustafa","year":"2018","journal-title":"Psychother Psychosom"},{"key":"2025082702230026000_26.1.e300771.8","doi-asserted-by":"publisher","DOI":"10.1038\/nrn.2015.19"},{"key":"2025082702230026000_26.1.e300771.9","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.bbi.2020.03.024","article-title":"Resolution of chronic inflammation as a new adjunctive approach in schizophrenia treatment","volume":"88","author":"Kalinkovich","year":"2020","journal-title":"Brain Behav Immun"},{"key":"2025082702230026000_26.1.e300771.10","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/S2215-0366(21)00383-7","article-title":"Towards better care for women with schizophrenia-spectrum disorders","volume":"9","author":"Brand","year":"2022","journal-title":"Lancet Psychiatry"},{"key":"2025082702230026000_26.1.e300771.11","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1176\/appi.ajp.2021.20111658","article-title":"20-year prospective, sequential follow-up study of heterogeneity in associations of duration of untreated psychosis with symptoms, functioning, and quality of life following first-episode psychosis","volume":"179","author":"O\u2019Keeffe","year":"2022","journal-title":"AJP"},{"key":"2025082702230026000_26.1.e300771.12","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.tips.2022.09.006","article-title":"Muscarinic acetylcholine receptors for psychotic disorders: bench-side to clinic","volume":"43","author":"Yohn","year":"2022","journal-title":"Trends Pharmacol Sci"},{"key":"2025082702230026000_26.1.e300771.13","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/JCP.0000000000001596","article-title":"A new treatment paradigm: targeting trace amine-associated receptor 1 (TAAR1) in schizophrenia","volume":"42","author":"Kane","year":"2022","journal-title":"J Clin Psychopharmacol"},{"key":"2025082702230026000_26.1.e300771.14","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1056\/NEJMoa1911772","article-title":"A non\u2013D2-receptor-binding drug for the treatment of schizophrenia","volume":"382","author":"Koblan","year":"2020","journal-title":"N Engl J Med"},{"key":"2025082702230026000_26.1.e300771.15","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41537-018-0064-6","article-title":"Efficacy of different types of cognitive enhancers for patients with schizophrenia: a meta-analysis","volume":"4","author":"Sinkeviciute","year":"2018","journal-title":"Npj Schizophr"},{"key":"2025082702230026000_26.1.e300771.16","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1176\/appi.ajp.2016.15081035","article-title":"Efficacy and safety of antidepressants added to antipsychotics for schizophrenia: a systematic review and meta-analysis","volume":"173","author":"Helfer","year":"2016","journal-title":"AJP"},{"key":"2025082702230026000_26.1.e300771.17","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/acps.12854","article-title":"Efficacy and safety of antidepressant augmentation of continued antipsychotic treatment in patients with schizophrenia","volume":"137","author":"Galling","year":"2018","journal-title":"Acta Psychiatr Scand"},{"key":"2025082702230026000_26.1.e300771.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2009.01.002"},{"key":"2025082702230026000_26.1.e300771.19","unstructured":"NICE . Psychosis and schizophrenia in adults: prevention and management. NICE, 2014."},{"key":"2025082702230026000_26.1.e300771.20","doi-asserted-by":"crossref","unstructured":"Irving CB , Mumby-Croft R , Joy LA , et al . Polyunsaturated fatty acid supplementation for schizophrenia. Cochrane Database Syst Rev 2006. doi:10.1002\/14651858.CD001257.pub2","DOI":"10.1002\/14651858.CD001257.pub2"},{"key":"2025082702230026000_26.1.e300771.21","unstructured":"Tsai GE , Lin P-Y . Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis"},{"key":"2025082702230026000_26.1.e300771.22","doi-asserted-by":"publisher","DOI":"10.2165\/11586650-000000000-00000"},{"key":"2025082702230026000_26.1.e300771.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2012.08.016"},{"key":"2025082702230026000_26.1.e300771.24","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e318248b7bb"},{"key":"2025082702230026000_26.1.e300771.25","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.10r06823"},{"key":"2025082702230026000_26.1.e300771.26","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbt139"},{"key":"2025082702230026000_26.1.e300771.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2012.08.014"},{"key":"2025082702230026000_26.1.e300771.28","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbt070"},{"key":"2025082702230026000_26.1.e300771.29","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.f185","article-title":"Early interventions to prevent psychosis: systematic review and meta-analysis","volume":"346","author":"Stafford","year":"2013","journal-title":"BMJ"},{"key":"2025082702230026000_26.1.e300771.30","doi-asserted-by":"publisher","DOI":"10.1002\/hup.2426"},{"key":"2025082702230026000_26.1.e300771.31","first-page":"289","article-title":"A meta-analysis of placebo-controlled trials of omega-3 fatty acid augmentation in schizophrenia: possible stage-specific effects","volume":"27","author":"Chen","year":"2015","journal-title":"Ann Clin Psychiatry Off J Am Acad Clin Psychiatr"},{"key":"2025082702230026000_26.1.e300771.32","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1017\/S1092852916000638","article-title":"Systematic review and meta-analysis of the efficacy and safety of minocycline in schizophrenia","volume":"22","author":"Solmi","year":"2017","journal-title":"CNS Spectr"},{"key":"2025082702230026000_26.1.e300771.33","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.euroneuro.2016.11.012","article-title":"Adjunctive minocycline for schizophrenia: a meta-analysis of randomized controlled trials","volume":"27","author":"Xiang","year":"2017","journal-title":"European Neuropsychopharmacology"},{"key":"2025082702230026000_26.1.e300771.34","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jpsychires.2017.04.004","article-title":"Adjunctive celecoxib for schizophrenia: a meta-analysis of randomized, double-blind, placebo-controlled trials","volume":"92","author":"Zheng","year":"2017","journal-title":"J Psychiatr Res"},{"key":"2025082702230026000_26.1.e300771.35","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/acps.12862","article-title":"N-Acetylcysteine for major mental disorders: a systematic review and meta-analysis of randomized controlled trials","volume":"137","author":"Zheng","year":"2018","journal-title":"Acta Psychiatr Scand"},{"key":"2025082702230026000_26.1.e300771.36","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1177\/0269881119858286","article-title":"Adjunctive minocycline for major mental disorders: a systematic review","volume":"33","author":"Zheng","year":"2019","journal-title":"J Psychopharmacol"},{"key":"2025082702230026000_26.1.e300771.37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41537-017-0043-3","article-title":"The effect of raloxifene augmentation in men and women with a schizophrenia spectrum disorder: a systematic review and meta-analysis","volume":"4","author":"de Boer","year":"2018","journal-title":"NPJ Schizophr"},{"key":"2025082702230026000_26.1.e300771.38","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00737-017-0773-2","article-title":"Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: a meta-analysis of randomized controlled trials","volume":"21","author":"Wang","year":"2018","journal-title":"Arch Womens Ment Health"},{"key":"2025082702230026000_26.1.e300771.39","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.schres.2018.01.017","article-title":"Adjunctive raloxifene for postmenopausal women with schizophrenia: a meta-analysis of randomized, double-blind, placebo-controlled trials","volume":"197","author":"Zhu","year":"2018","journal-title":"Schizophrenia Research"},{"key":"2025082702230026000_26.1.e300771.40","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1177\/0269881118822157","article-title":"Effect of N-methyl-D-aspartate-receptor-enhancing agents on cognition in patients with schizophrenia: a systematic review and meta-analysis of double-blind randomised controlled trials","volume":"33","author":"Chang","year":"2019","journal-title":"J Psychopharmacol"},{"key":"2025082702230026000_26.1.e300771.41","doi-asserted-by":"publisher","DOI":"10.1177\/0269881120908016"},{"key":"2025082702230026000_26.1.e300771.42","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1177\/0004867419835028","article-title":"Adjunctive use of anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials","volume":"53","author":"Cho","year":"2019","journal-title":"Aust N Z J Psychiatry"},{"key":"2025082702230026000_26.1.e300771.43","doi-asserted-by":"publisher","DOI":"10.1111\/eip.12677"},{"key":"2025082702230026000_26.1.e300771.44","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1017\/S0033291719001995","article-title":"An update on the efficacy of anti-inflammatory agents for patients with schizophrenia: a meta-analysis","volume":"49","author":"\u00c7akici","year":"2019","journal-title":"Psychol Med"},{"key":"2025082702230026000_26.1.e300771.45","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.bbi.2020.08.028","article-title":"Efficacy and safety of anti-inflammatory agents in treatment of psychotic disorders - A comprehensive systematic review and meta-analysis","volume":"90","author":"Jeppesen","year":"2020","journal-title":"Brain, Behavior, and Immunity"},{"key":"2025082702230026000_26.1.e300771.46","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1177\/0004867419893439","article-title":"Meta-analysis of randomised controlled trials with N-Acetylcysteine in the treatment of schizophrenia","volume":"54","author":"Yolland","year":"2020","journal-title":"Aust N Z J Psychiatry"},{"key":"2025082702230026000_26.1.e300771.47","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1177\/0269881120965937","article-title":"Efficacy of N-methyl-D-aspartate receptor modulator augmentation in schizophrenia: a meta-analysis of randomised, placebo-controlled trials","volume":"35","author":"Goh","year":"2021","journal-title":"J Psychopharmacol"},{"key":"2025082702230026000_26.1.e300771.48","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1177\/0269881120981392","article-title":"Effects of omega-3 polyunsaturated fatty acids supplements on psychopathology and metabolic parameters in schizophrenia: a meta-analysis of randomized controlled trials","volume":"35","author":"Goh","year":"2021","journal-title":"J Psychopharmacol"},{"key":"2025082702230026000_26.1.e300771.49","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1080\/17425255.2021.1885648","article-title":"Sarcosine as an add-on treatment to antipsychotic medication for people with schizophrenia: a systematic review and meta-analysis of randomized controlled trials","volume":"17","author":"Marchi","year":"2021","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2025082702230026000_26.1.e300771.50","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1080\/15622975.2018.1557346","article-title":"WFSBP guidelines on how to grade treatment evidence for clinical guideline development","volume":"20","author":"Hasan","year":"2019","journal-title":"World J Biol Psychiatry"},{"key":"2025082702230026000_26.1.e300771.51","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1080\/15622975.2021.2013041","article-title":"Clinician guidelines for the treatment of psychiatric disorders with nutraceuticals and phytoceuticals: the world federation of societies of biological psychiatry (WFSBP) and Canadian network for mood and anxiety treatments (CANMAT) taskforce","volume":"23","author":"Sarris","year":"2022","journal-title":"World J Biol Psychiatry"},{"key":"2025082702230026000_26.1.e300771.52","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1177\/0706743717719894","article-title":"Canadian treatment guidelines on psychosocial treatment of schizophrenia in adults","volume":"62","author":"Norman","year":"2017","journal-title":"Can J Psychiatry"},{"key":"2025082702230026000_26.1.e300771.53","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.schres.2019.09.013","article-title":"Antipsychotic treatment in the maintenance phase of schizophrenia: an updated systematic review of the guidelines and algorithms","volume":"215","author":"Shimomura","year":"2020","journal-title":"Schizophrenia Research"},{"key":"2025082702230026000_26.1.e300771.54","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/s41386-019-0573-7","article-title":"Factors associated with successful antipsychotic dose reduction in schizophrenia: a systematic review of prospective clinical trials and meta-analysis of randomized controlled trials","volume":"45","author":"Tani","year":"2020","journal-title":"Neuropsychopharmacol"},{"key":"2025082702230026000_26.1.e300771.55","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/S2215-0366(21)00078-X","article-title":"Standard versus reduced dose of antipsychotics for relapse prevention in multi-episode schizophrenia: a systematic review and meta-analysis of randomised controlled trials","volume":"8","author":"H\u00f8jlund","year":"2021","journal-title":"Lancet Psychiatry"},{"key":"2025082702230026000_26.1.e300771.56","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1001\/jamapsychiatry.2021.2130","article-title":"Examination of dosing of antipsychotic drugs for relapse prevention in patients with stable schizophrenia: a meta-analysis","volume":"78","author":"Leucht","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"2025082702230026000_26.1.e300771.57","doi-asserted-by":"crossref","unstructured":"Cochrane Schizophrenia Group, Rodolico A , Siafis S , et al . Antipsychotic dose reduction compared to dose continuation for people with schizophrenia. Cochrane Database Syst Rev 2022;2022. doi:10.1002\/14651858.CD014384.pub2","DOI":"10.1002\/14651858.CD014384.pub2"},{"key":"2025082702230026000_26.1.e300771.58","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41537-022-00214-2","article-title":"Reduced erythrocyte membrane polyunsaturated fatty acid levels indicate diminished treatment response in patients with multi- versus first-episode schizophrenia","volume":"8","author":"Li","year":"2022","journal-title":"Schizophr"},{"key":"2025082702230026000_26.1.e300771.59","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2013.110","article-title":"A randomized placebo-controlled trial of an omega-3 fatty acid and vitamins E+C in schizophrenia","volume":"3","author":"Bentsen","year":"2013","journal-title":"Transl Psychiatry"},{"key":"2025082702230026000_26.1.e300771.60","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1093\/schbul\/sbaa198","article-title":"Adjunctive aspirin vs placebo in patients with schizophrenia: results of two randomized controlled trials","volume":"47","author":"Weiser","year":"2021","journal-title":"Schizophr Bull"},{"key":"2025082702230026000_26.1.e300771.61","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-9964(00)00088-8"},{"key":"2025082702230026000_26.1.e300771.62","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1001\/jamapsychiatry.2017.0624","article-title":"Efficacy of 42 pharmacologic cotreatment strategies added to antipsychotic monotherapy in schizophrenia: systematic overview and quality appraisal of the meta-analytic evidence","volume":"74","author":"Correll","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"2025082702230026000_26.1.e300771.63","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s12874-018-0554-2","article-title":"Quality of randomized controlled trials of new generation antidepressants and antipsychotics identified in the China National knowledge infrastructure (CNKI): a literature and telephone interview study","volume":"18","author":"Tong","year":"2018","journal-title":"BMC Med Res Methodol"},{"key":"2025082702230026000_26.1.e300771.64","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbaa153"},{"key":"2025082702230026000_26.1.e300771.65","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.schres.2016.12.021","article-title":"Childhood trauma, depression and negative symptoms are independently associated with impaired quality of life in schizophrenia. results from the National FACE-SZ cohort","volume":"185","author":"Andrianarisoa","year":"2017","journal-title":"Schizophrenia Research"},{"key":"2025082702230026000_26.1.e300771.66","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2013.12.014"},{"key":"2025082702230026000_26.1.e300771.67","doi-asserted-by":"publisher","DOI":"10.1002\/wps.20672"}],"container-title":["BMJ Mental Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjment-2023-300771","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T09:23:15Z","timestamp":1756286595000},"score":1,"resource":{"primary":{"URL":"https:\/\/mentalhealth.bmj.com\/lookup\/doi\/10.1136\/bmjment-2023-300771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,10,18]]},"published-print":{"date-parts":[[2023,10]]}},"alternative-id":["10.1136\/bmjment-2023-300771"],"URL":"https:\/\/doi.org\/10.1136\/bmjment-2023-300771","relation":{},"ISSN":["2755-9734"],"issn-type":[{"value":"2755-9734","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10]]}}}